Can Neil Woodford’s reputation survive three years of under-performance?

Neil Woodford’s annus horribilis has emboldened his detractors, but Harvey Jones is standing by his man for now.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You have to feel sorry for the super-successful, super-wealthy star fund manager Neil Woodford, who is suddenly in the headlines for the wrong reasons. After three decades of stonking outperformance, the knives are flashing. One annus horribilis is all it takes. Well, arguably, three years. So is the great man finished? Could be. It can happen to the best.


August’s headlines made ugly reading. “Star investor Woodford hit by fortnight from hell.” “Yet another Woodford debacle.” “What’s going wrong with Woodford?” And those are the polite ones. One or two I would blush to repeat here.

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

Things came to a head with the Provident Financial meltdown. Woodford owns a 19% stake in the doorstep lender and lost £326m when its shares crashed almost 70% in a day. Bad news comes in threes, the superstitious say, and Woodford has suffered a triple blow this year. In July, pharmaceuticals giant AstraZeneca, the biggest holding in CF Woodford Equity Income, plunged 15%, its largest ever fall. In April, outsize holding Allied Minds also suffered its biggest ever drop (Woodford holds more than a quarter of its stock).

Earnestly speaking

As Oscar Wilde might have put it: To suffer one high-profile stock meltdown, Mr Woodford, may be regarded as a misfortune, to have two looks like carelessness. But three? Actually, I count four, including biotech stock Sphere Medical Holdings, which features in his dismal Patient Capital Trust. Wilde said nothing about four indignities, which turns into five if you include the AA, whose shares tanked after chief executive Bob Mackenzie’s alleged bar punch-up madenews.

I have made good money from his triumphant Invesco Perpetual Income fund, so I owe a degree of loyalty. He has shown similar loyalty to his stock picks, routinely rushing to their defence, claiming for example that Provident Financial is now seriously undervalued.

Sinking ship

So let’s visit to examine the performance of his flagship CF Woodford Equity Income, launched in June 2014. The £9.25bn fund is down -0.3% over the last year while its benchmark UK equity income sector is up a buoyant 10.5%. Embarrassingly, it is the sector’s worst performer over three, six and 12 months and is only keeping its head above water thanks to a stonking first year, when it grew 16% against 2.8% for its sector.

Over three years Woodford has posted a second quartile showing of 25.2% but does not trouble the top 10. First-placed MI Chelverton UK Equity Income returned 41.6%, while even 10th-placed Neptune Income beat Woodford with 31.1%.

Patient diagnosis

Woodford Patient Capital Trust has done worse, rising 3.8% in the last year against 16.3% on the All Companies index, after falling 18.5% the year before, against a 1.1% rise. I think there is a serious danger that Woodford is out of his depth here in his pursuit of smaller quoted and unquoted companies.

I will continue to hold CF Woodford Equity Income. Woodford has suffered periods of underperformance before and emerged with his reputation enhanced. However, that was often through making heroic contrarian calls, such as shunning booming tech and banking stocks. His recent troubles are down to poor stock picking, which is less heroic.

Woodford does invest in a lot of companies, and some will go wrong. But maybe running his own asset management company was a step too far? I detect signs of arrogance. Despite all this, I still reckon his star will shine again.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Harvey Jones hold units in Invesco Perpetual Income and CF Woodford Equity Income. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Should you invest the value of your investment may rise or fall and your Capital is at Risk. Before investing your individual circumstances should be considered, so you should consider taking independent financial advice.

More on Investing Articles

Passive and Active: text from letters of the wooden alphabet on a green chalk board
Investing Articles

2 undervalued passive income stocks I’d buy today with £1,000

Falling stock prices are pushing up dividend yields. As a result, our author is looking for undervalued passive income stocks…

Read more »

Close-up of British bank notes
Investing Articles

2 cheap dividend shares I’d buy in a heartbeat

Our writer picks a pair of FTSE 100 dividend shares he would consider for his portfolio, that he thinks look…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

With £500, I’d use the Warren Buffett method to find cheap shares

The legendary investor Warren Buffett has become a billionaire by following some key investment principles. Our writer explains why he…

Read more »

Man in a clothing store in a medical mask because of a coronovirus.
Investing Articles

Down 81%, are boohoo shares set for an explosive comeback?

boohoo shares have been falling rapidly. But could interest from a billion-dollar hedge fund cause a turnaround in 2022?

Read more »

Smartly dressed middle-aged black gentleman working at his desk
Investing Articles

The Tullow Oil (TLW) share price jumps after losses! Is now the time to buy?

The Tullow Oil (TLW) share price ticked upwards on Thursday morning after falling nearly 30% over the last month. So,…

Read more »

Female analyst sat at desk looking at pie charts on paper
Investing Articles

Is the Lloyds share price about to dip below 40p?

The Lloyds share price has been trading below 50p for the better part of the year. But could the stock…

Read more »

Cheerful young businesspeople with laptop working in office
Investing Articles

2 beaten-down FTSE 250 shares I’m buying and holding for the long term

Andrew Woods explains why he's adding two FTSE 250 shares to his portfolio in the middle of a market sell-off.

Read more »

Female analyst sat at desk looking at pie charts on paper
Investing Articles

The Legal & General (LGEN) share price jumps 3%! Am I too late to buy?

The Legal & General (LGEN) share price soared in early trading on Thursday as the company registered a good start…

Read more »